Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients

103Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

Abstract

Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD) syndrome is an important contributor to the CKD-associated cardiovascular disease and high mortality rates. Sclerostin, a protein synthesized in osteocytes, is a potent downregulator of bone metabolism and a novel candidate for the bone-vascular axis in CKD patients. We tested whether serum sclerostin values are predictive for all-cause mortality and cardiovascular events (CVEs) in a CKD population. Methods: Serum sclerostin was obtained from 173 CKD (stage 3-5) and 47 control patients, and its concentration was correlated with estimated glomerular filtration rate and to mineral and vascular abnormalities that are present in the CKD evolution. All-cause mortality and CVEs were also analyzed in relation to serum sclerostin values. Results: Patients with CKD showed higher sclerostin levels (median 63.5 pmol/L vs 52 pmol/L, P

References Powered by Scopus

Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

28078Citations
N/AReaders
Get full text

A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation

13830Citations
N/AReaders
Get full text

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

10057Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The chronic kidney disease — Mineral bone disorder (CKD-MBD): Advances in pathophysiology

156Citations
N/AReaders
Get full text

Sclerostin and DKK1: New players in renal bone and vascular disease

120Citations
N/AReaders
Get full text

Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification

118Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kanbay, M., Siriopol, D., Saglam, M., Kurt, Y. G., Gok, M., Cetinkaya, H., … Yilmaz, M. I. (2014). Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. Journal of Clinical Endocrinology and Metabolism, 99(10), E1854–E1861. https://doi.org/10.1210/jc.2014-2042

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

48%

Professor / Associate Prof. 8

24%

Researcher 6

18%

Lecturer / Post doc 3

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 24

80%

Biochemistry, Genetics and Molecular Bi... 3

10%

Agricultural and Biological Sciences 2

7%

Pharmacology, Toxicology and Pharmaceut... 1

3%

Save time finding and organizing research with Mendeley

Sign up for free
0